Nyxoah: Funding, Investors & Team (Sep 2026)
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
Nyxoah has raised $15.0M across 1 funding round on record, the most recent an undisclosed round of $15.0M announced in Jun 2026.
That round is above the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Nyxoah Company Profile and Key Stats
Latest funding round on record: Jun 2026.
Nyxoah Funding Rounds
Nyxoah Founders and Leadership Team
Contact details for the Nyxoah team: 1 of 1 has an email address on file.
Start 14-day free trial →Nyxoah Funding Compared to Other Biotechnology Startups
Nyxoah's latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Nyxoah in Biotechnology and Mont-saint-guibert
Companies Similar to Nyxoah
MAASH is a biotech mycoprotein producing company that supply a nutritious and health feed and food protein…
Turning biomass residues into fit-for-purpose microbial fertilizers, biostimulants and biocontrols.
Coultreon Biopharma is developing best-in-class therapeutics that target clinically validated pathways in…
neuroClues provides easy-to-use eye-tracking environment to help practitioners instantaneously quantify their…
Trince is advancing cell-based science and therapeutics by facilitating the delivery of molecules into cells,…
Confo Therapeutics is a company focused on drug discovery, specifically targeting GPCRs to address medical…
Animab is a biotech company that focuses on developing unique technology to enhance the health of livestock.…
Augustine Therapeutics company is conducting two drug discovery programs in order to discover new generations…
4Tissue is a company focused on research and clinical trials that creates remedies to address the challenges…
Tavira Therapeutics creates an innovative platform to improve the delivery of genes using AAV. By adding…
AgomAb is creating sub-atomic treatments for the recovery of harmed tissues. Their exceptional agonistic…
BioSourcing is developing a New Generation of Biotherapeutics, in particular Monoclonal Antibodies for Global…
Nyxoah Funding FAQs
What does Nyxoah do?
Nyxoah is a health-technology company focused on the development and commercialization of innovative solutions and services to treat sleep disordered breathing conditions. Nyxoah's lead solution platform is based on the Genio® system, a validated, user-centered, next generation neurostimulation therapy for OSA, the world's most common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
How much funding has Nyxoah raised?
Nyxoah has raised $15.0M across 1 round on record. The most recent is an undisclosed round of $15.0M announced in Jun 2026.
When did Nyxoah last raise funding?
Nyxoah's most recent funding round on record is an undisclosed round of $15.0M, announced in Jun 2026.
Who founded Nyxoah?
FundedIQ lists Olivier Taelman (Founder) at Nyxoah.
Where is Nyxoah headquartered?
Nyxoah is based in Mont-saint-guibert, Brabant Wallon, Belgium.
How many employees does Nyxoah have?
Nyxoah is in the 101-250 employee band.
How does Nyxoah's funding compare to other Biotechnology startups?
Nyxoah's latest round of $15.0M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,179 tracked companies over the last two years.
About FundedIQ's Nyxoah Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Nyxoah is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.